Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2023-04-25 Notice of Dividend Amou…
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
2022 年年度权益分派预案公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the 2022 annual profit distribution plan (dividend distribution plan) of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the proposed cash dividend per share, the total amount to be distributed, the approval process involving the board of directors and shareholders' meeting, and the company's dividend policy and related procedures. It does not contain full financial statements or comprehensive financial performance data but focuses on the dividend amount and distribution plan. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2023-04-25 Chinese
独立董事关于第二届董事会第十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several company matters related to the second board meeting of the company. It includes opinions on the internal control self-evaluation report for 2022, the special report on the use of raised funds in 2022, the 2022 profit distribution plan, the 2023 related party transactions plan, and the proposal to reappoint the audit firm for 2023. The document is a formal statement of independent directors' opinions on these agenda items, which are typically part of board meeting materials or announcements related to board decisions. It does not contain full financial statements or detailed financial data, nor is it a full annual report or audit report. It is not a call transcript, earnings release, or other types of filings. The document is best classified as Board/Management Information (MANG) because it relates to board meeting opinions and approvals on key company matters.
2023-04-25 Chinese
财通证券股份有限公司关于江西新赣江药业股份有限公司2022 年度公司治理专项自查及规范活动的专项核查报告
Regulatory Filings
2023-04-25 Chinese
第二届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangxi New Ganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on various agenda items including approval of the 2022 Supervisory Board Work Report, 2022 Annual Report, internal control self-evaluation report, governance self-inspection report, fundraising usage report, profit distribution plan, and expected related party transactions for 2023. The document references other reports published separately on the Beijing Stock Exchange information disclosure platform, indicating this document itself is a meeting resolution announcement rather than the reports themselves. The document is relatively short (2264 characters) and does not contain the full reports or detailed financial data. It is an official announcement of meeting resolutions and voting results by the Supervisory Board, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Annual Report (10-K) or Declaration of Voting Results (DVA).
2023-04-25 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告 2022' which translates to 'Annual Report 2022'. It contains detailed sections typical of an annual report such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management information, industry information, corporate governance, internal control, and financial accounting reports. The document includes audited financial data, management certifications, and auditor's unqualified opinion, all consistent with a comprehensive annual report. The length of the document (15,000 characters) and the detailed financial and operational data confirm it is the full annual report rather than an announcement or summary. Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2023-04-25 Chinese
独立董事关于第二届董事会第十九次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from independent directors providing their prior approval opinions on matters to be discussed at a board meeting, specifically regarding the reappointment of the auditing firm for the 2023 fiscal year and anticipated related party transactions. It references the company's articles of association, the Company Law of China, and the independent director system. The content is about board-level approvals and opinions rather than a full audit report or financial statements. The document length is short (847 characters), and it is clearly an announcement of board/management information related to governance and approvals. Therefore, it fits best under Board/Management Information (MANG).
2023-04-25 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.